25764669
2015 Feb
The antiviral therapy for chronic hepatitis C has been developed since HCV was discovered in 1989. As for the patients with genotype 1, sustained virological response rate by interferon monotherapy was less than 20% in 1990's; the rate has been improved today to 85% by direct-acting antivirals. The prevention of development of liver cirrhosis and hepatocellular carcinoma will be expected.

